Top of page Skip navigation

Business Workshop

One hour interactive sessions focusing on specific business and operational challenges faced by biotech companies. 

13 July 

13.30: Early Stage Funding

A one hour interactive workshop to hear from the main government funding support available to biotech start-ups and how to access them. But also to get an understanding of what to expect from seed investors' term sheets and ensure the attractivity of your start-up to them.  

Richard Hebdon, Innovate UK
Alexandra Richardson, Taylor Wessing
Fiona MaclaughlinJohnson & Johnson Innovation – JJDC, Inc

14.30: IP Due Diligence 

An overview of the main term sheets requirements in terms of Intellectual Property including freedom to operate, warranties and discussion on how to get them right.

Teresa Lavoie, Fish&Richardson
Colin McCall, Taylor Wessing

15.30: Preparing for the Next Phase 

Session Sponsor:

In this session, we will look at the various different ways in which life sciences companies can take their business to the next phase, whether by way of a sale, listing, further funding and development, commercialisation, licensing or partnering.  We’ll also explore the crossover to the US with thanks to Mintz.  

Chair: James Fry, Head of Life Sciences, Mills & Reeve

William Hicks, Mintz, United States
Kristian Shearsby, Mills & Reeve
Katharine Robinson, Mills & Reeve


14 July 

10.00: Communications 101  - Telling, Selling and Propelling Your Story

This workshop will cover how to communicate your science, strategy and services across multiple formats from technical articles to tweets including partnering messages and meetings. Throughout the session, we will focus on your target audience and the key messages you need to get across to get their buy in.

Claire Thompson, Agility Health Tech

11.00: Confidence in Employees - Best practices in employement agreements relating to IP and confidential information

Rachel Bradley, Penningtons Manches Cooper
Sophie Whitbread, Penningtons Manches Cooper

12.00: Preclinical Dataset  
Reducing Risks In Early Drug Development: From Drug Candidate to Phase 1 Clinical Testing

Achieving success in early development is essential in progressing a drug molecule’s next milestone. Addressing issues early and comprehensively in the development life-cycle can result in fewer problems down the line such as escalating timelines, reformulating issue due to ADMEs issues, costs and regulatory issues. Therefore, It is important to leverage the skills and experiences of pharmaceutical scientists at the earliest stages of development to optimize and enable drug candidates to reach their true potential.

Ian Barker, Catalent


Headline Sponsor



Media Sponsor